Dermatology

In her DERM 2025 conference interview, Martinez-Dulay highlights takeaways from her sessions on atopic dermatitis, prurigo nodularis, and lymphoma.

Cotter highlights his DERM 2025 conference presentation on navigating the diagnosis of melanoma and gene expression profiling of skin cancer.

Elkady joins the program to discuss her experience transitioning from patient care to clinical trials and industry.

This interview with Cotter highlights his session on the use of AI tools in the dermatology field.

This interview with Hure covers 2 of her sessions at DERM 2025, including a discussion of microplastics and forever chemicals, as well as the skin’s microbiome.

Swanson speaks in this interview segment about her DERM 2025 session on speaking with parents and their children or teens as a clinician.

This interim data was drawn from the TRACE study, highlighting real-world use of tralokinumab in adults with atopic dermatitis of the head and neck.

In this interview, Swanson highlights her DERM 2025 session ‘Systemic Therapy for the Pediatric Acne Patient’ and its takeaways.

In this DERM2025 interview, Friedman highlighted some of the discussion points from his presentation on off-label strategies for therapeutic challenges.

In this interview segment with Chilukuri, he highlights takeaways from his DERM 2025 session titled ‘Advancements in Body Contouring.’

In this discussion with Chilukuri, the most notable highlights from his DERM 2025 session ‘Skincare Secrets and Quick Fixes’ were covered.

In this interview, Friedman highlights notable points from his DERM 2025 talk on managing patients with tinea.

In a new interview at the DERM2025 Conference, Boswell highlights a session on systemic drugs and another session on wart and molluscum imitators.

In a new interview at the DERM2025 Conference, Stein Gold highlighted several topical options for patients with psoriasis outside of topical steroids.

This interview with Friedman highlights the takeaways from his DERM 2025 session on managing chronic pruritus in dermatology.

In an ADvocate study subpopulation, new findings suggest lebrikizumab therapy leads to significant disease control and positive itch impacts.

This summary highlights changes in severe alopecia areata following deuruxolitinib therapy during THRIVE-AA1 and THRIVE-AA2.

This summary of the phase 3 ALLEGRO-LT study highlights several notable findings on ritlecitinib’s use among adults and adolescents with alopecia areata.

This interview with Song at DERM2025 highlights recent phase 3 data on risankizumab for genital and scalp psoriasis.

FDA approval of topical delgocitinib marks a long-awaited treatment milestone for adults with chronic hand eczema.

A new analysis found a 0.78% prevalence of CSU in US adults, exceeding earlier estimates, and revealed significant mental, physical, and work-related burdens.

FDA approves delgocitinib cream, offering a new treatment option for adults with moderate-to-severe chronic hand eczema.

This study evaluated a set of key AI outputs: skin tone representation and diagnostic accuracy of generated dermatologic diseases.

This case–control study compared sleep quality, risk of obstructive sleep apnoea, and quality of life between those with psoriasis and healthy controls.

The announcement of this NDA submission to the FDA highlights icotrokinra, a first-in-class investigational targeted oral peptide for plaque psoriasis.